Home
/ ABL Bio

ABL Bio

ABL Bio

Total Funding

$90.8 M

ABL Bio Summary

Company summary

Overview: ABL Bio is a biotech research company focusing on the development of therapeutic drugs for immuno-oncology and neurodegenerative disease. It offers a range of bispecific antibody platforms.

Type: Private

Status: Active

Founded: 2016

Website: https://www.ablbio.com/

Cybersecurity rating

ESG rating: 40-49 out of 100|View all ESG data

Sectors

Competitors and similar companies

Compare competitors

News

Insights on the Antibody Drug Conjugates Global Market to 2030 - Featuring 6 Dimensions Capital, AbbVie and ABL Bio Among Others

Oct 8, 2021

ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody

Aug 4, 2021

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

Jul 9, 2021

I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

Mar 30, 2021